Cerba Research at the World Vaccine Congress Washington 2024
We’re proud to be part of this year’s WVC, working together with our colleagues and partners in the industry to prepare for future pandemics and enable faster and more effective virus vaccine developments.
We are committed to providing solutions to the greatest challenges in vaccine development today and tomorrow, constantly setting the standards to protect the world against infectious disease.
Viroclinics-DDL changes name to Cerba Research
End-to-end vaccine and antiviral drug development
Our acquisition of Viroclinics-DDL has further added to our world-class operational expertise, and developed the logistical infrastructure and scientific rigor needed to effectively characterize, research, and treat infectious diseases as they emerge.
Over 600 infectious disease studies supported in the past 5 years
90%+ of our infectious disease studies involve specialty testing
A strong track record in influenza, SARS-CoV-2, RSV, HBV, Polio, HPV, CMV and more
One of only 5 commercial laboratories involved in CEPI, forming part of the worldwide response to diseases
We work with the NIAID, NIH and the Bill and Melinda Gates Foundation, and are part of the CEPI alliance
Established footprint in Africa – over 100 clinical pathology laboratories for logistics and routine testing
Visit us at Booth 307
We’re excited to meet with our colleagues across the industry – so do come and say hello. You can find us at Booth 307, where our team of experts is ready to answer your questions, share ideas, and tell you more about our unique virology capabilities. Why not join us for a chat at cocktail hour?
Speaking slot – Meet our experts
The Cerba Research team will also be speaking at 2 speaking slots during the Congress, sharing their insights and experience and being present at the booth, where you’re welcome to come, meet and talk with them.
The role of PBMC is a critical factor to understand vaccine effectiveness: Wednesday 3rd April 9:10am, 30 minutes
Nele Langenaken
General Manager, Cerba Research USA
The role of PBMC is a critical factor to understand vaccine effectiveness
What routes are there to prepare your PBMC network
Considerations for further downstream analysis including FCM, ELLIspot, NGS……
Setting up your network, global considerations, cold chain, from vein to result, long term storage
Lessons learned / case study
Pandemic Preparedness: from Proof of Concept to Clinic: Wednesday 3rd April 10:10am, 30 minutes
Leon de Waal
Principal Scientist Preclinical Services, Cerba Research Netherlands
Preclinical model development
Assay development (from implementation to validation)
Logistical challenges
Please get in touch to learn more about our infectious disease and virology services. You can either:
Reach out to our experts and discover how we are setting the standards to protect the world against infectious diseases. You can also find out more about our vaccine lab services.
